Phase II trial of weekly alternating sequential BIBF 1120 and afatinib for advanced colorectal cancer

Anticancer Research

Volumn 31, Issue 6, 2011, Pages 2271-2281

  Bouche, Olivier ^a   Maindrault Goebel, Frederique ^b   Ducreux, Michel ^c   Lledo, Gerard ^d   Andre, Thierry ^e   Stopfer, Peter ^f   Amellal, Nadia ^g   Merger, Michael ^f   De Gramont, Aimery ^b  

^a REIMS UNIVERSITY HOSPITAL   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d Clinique Saint Jean   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^g BOEHRINGER INGELHEIM   (France)

Author keywords

Afatinib; BIBF 1120; Colorectal cancer; Pharmacokinetics; Phase II

Indexed keywords

AFATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; INTEDANIB; VASCULOTROPIN;

ABDOMINAL PAIN; ACNE; ADVANCED CANCER; ANEMIA; ANOREXIA; ARTHRALGIA; ASCITES; ASTHENIA; BACKACHE; BLOOD DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; CONFERENCE PAPER; CONNECTIVE TISSUE DISEASE; CONSTIPATION; DEHYDRATION; DERMATITIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; EPISTAXIS; ERYTHEMA; FEASIBILITY STUDY; FEVER; HEADACHE; HUMAN; HYPERTENSION; KIDNEY FAILURE; LYMPHATIC DISORDER; MALAISE; METABOLIC DISORDER; MONOTHERAPY; MUCOSAL INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA AND VOMITING; NUTRITIONAL DISORDER; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SIDE EFFECT; SKIN DEFECT; SURVIVAL RATE; SURVIVAL TIME; UROGENITAL TRACT DISEASE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; INDOLES; MALE; MIDDLE AGED; QUINAZOLINES; SURVIVAL RATE;

EID: 79960443101     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (63)

1. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E and Sarkar S: Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23: 3706-3712, 2005.
2. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F and Cassidy J: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26: 2013-2019, 2008.
3. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R and Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004. (Pubitemid 38702844)
4. Griesinger F, Pavlakis N, Garrido P, Dansin EE, L. Crinò L, N. Thatcher N, J. Laskin J, Zhou C, Kohlhäufl MJ, Tsai C-M and group obotMSs. MO19390 (SAIL): safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with a advanced or recurrent non-squamous non-small cell lung cancer (NSCLC). World Lung Cancer Congress Proceedings, San Francisco, CA, USA, 2009. Abstract C352.356.
5. Nicholson RI, Gee JM and Harper ME: EGFR and cancer prognosis. Eur J Cancer 37(Suppl 4): S9-15, 2001.
6. Cappuzzo F: EGFR FISH versus mutation: different tests, different end-points. Lung Cancer 60: 160-165, 2008.
7. Bailey R, Kris M, Wolf M, Kay A, Averbuch S, Askaa J, Janas M, Schmidt K and Fukuoka M: Gefitinib ('Iressa', ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer in IDEAL 1 and 2: tumor response is not clinically relevantly predictable from tumor EGFR membrane staining alone. Lung Cancer 41: S71, 2003.
8. Hoda D, Simon GR and Garrett CR: Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab. Ther Clin Risk Manag 4: 1221-1227, 2008.
9. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I and Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345, 2004. (Pubitemid 38944402)
10. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C and Moore MJ: Cetuximab for the treatment of colorectal cancer. N Engl J Med 357: 2040-2048, 2007.
11. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M and Amado RG: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25: 1658-1664, 2007. (Pubitemid 46797944)
12. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J and Rougier P: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360: 1408-1417, 2009.
13. Cappuzzo F, Gregorc V, Rossi E, Cancellieri A, Magrini E, Paties CT, Ceresoli G, Lombardo L, Bartolini S, Calandri C, de Rosa M, Villa E and Crino L: Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol 21: 2658-2663, 2003.
14. Cappuzzo F, Magrini E, Ceresoli GL, Bartolini S, Rossi E, Ludovini V, Gregorc V, Ligorio C, Cancellieri A, Damiani S, Spreafico A, Paties CT, Lombardo L, Calandri C, Bellezza G, Tonato M and Crino L: AKT phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 96: 1133-1141, 2004. (Pubitemid 39207049)
15. Daniele L, Macri L, Schena M, Dongiovanni D, Bonello L, Armando E, Ciuffreda L, Bertetto O, Bussolati G and Sapino A: Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens. Mol Cancer Ther 6: 1223-1229, 2007. (Pubitemid 46711985)
16. Kosaka T, Yatabe Y, Endoh H, Yoshida K, Hida T, Tsuboi M, Tada H, Kuwano H and Mitsudomi T: Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 12: 5764-5769, 2006. (Pubitemid 44629607)
17. Hirsch FR, Varella-Garcia M and Cappuzzo F: Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene 28(Suppl 1): S32-37, 2009.
18. Johnson BE, Jackman D and Janne PA: Impact of EGFR mutations on treatment of non-small cell lung cancer. . Cancer Chemother Pharmacol 58: 5-9, 2006.
19. Kim TY, Han SW and Bang YJ: Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives. Expert Rev Mol Diagn 7: 821-836, 2007.
20. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F and Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947, 2000. (Pubitemid 30644117)
21. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC and Alberts SR: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22: 23-30, 2004. (Pubitemid 41095110)
22. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL and Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343: 905-914, 2000.
23. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L and Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355: 1041-1047, 2000. (Pubitemid 30162806)
24. Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, Andre T, Tabah-Fisch I and de Gramont A: OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a Stop-and-Go fashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol 24: 394-400, 2006. (Pubitemid 46630458)
25. Gazdar AF: Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 28(Suppl 1): S24-31, 2009.
26. Yung TK, Chan KC, Mok TS, Tong J, To KF and Lo YM: Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res 15: 2076-2084, 2009.
27. Nomoto K, Tsuta K, Takano T, Fukui T, Yokozawa K, Sakamoto H, Yoshida T, Maeshima AM, Shibata T, Furuta K, Ohe Y and Matsuno Y: Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis. Am J Clin Pathol 126: 608-615, 2006.
28. Fukui T, Ohe Y, Tsuta K, Furuta K, Sakamoto H, Takano T, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Asamura H, Tsuchida T, Kaneko M, Kusumoto M, Yamamoto S, Yoshida T and Tamura T: Prospective study of the accuracy of EGFR mutational analysis by high-resolution melting analysis in small samples obtained from patients with non-small cell lung cancer. Clin Cancer Res 14: 4751-4757, 2008.
29. Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B and Kerbel RS: Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151: 1523-1530, 1997. (Pubitemid 27527914)
30. Ellis PM, Kaiser R, Zhao Y, Stopfer P, Gyorffy S and Hanna N: Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients. Clin Cancer Res 16: 2881-2889, 2010.
31. Hirata A, Ogawa S, Kometani T, Kuwano T, Naito S, Kuwano M and Ono M: ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 62: 2554-2560, 2002. (Pubitemid 34462734)
32. Kim SJ, Uehara H, Karashima T, Shepherd DL, Killion JJ and Fidler IJ: Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin Cancer Res 9: 1200-1210, 2003. (Pubitemid 36323730)
33. Ciardiello F, Caputo R, Damiano V, Troiani T, Vitagliano D, Carlomagno F, Veneziani BM, Fontanini G, Bianco AR and Tortora G: Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 9: 1546-1556, 2003. (Pubitemid 36418413)
34. Molina-Vila MA, Bertran-Alamillo J, Reguart N, Taron M, Castella E, Llatjos M, Costa C, Mayo C, Pradas A, Queralt C, Botia M, Perez-Cano M, Carrasco E, Tomas M, Mate JL, Moran T and Rosell R: A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells. J Thorac Oncol 3: 1224-1235, 2008.
35. Kawada I, Soejima K, Watanabe H, Nakachi I, Yasuda H, Naoki K, Kawamura M, Eguchi K, Kobayashi K and Ishizaka A: An alternative method for screening EGFR mutation using RFLP in non-small cell lung cancer patients. J Thorac Oncol 3: 1096-1103, 2008.
36. Schiller JH: Small cell lung cancer: defining a role for emerging platinum drugs. Oncology 63: 105-114, 2002.
37. Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, Melnyk O, Ramies D, Lin M and Sandler A: Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 25: 4743-4750, 2007. (Pubitemid 350086476)
38. Herbst R, Sun Y, Eberhardt W, Germonpré P, Saijo N, Zhou C, Wang J, Li L, Kabbinavar F, Ichinose Y, Qin S, Zhang L, Biesma B, Heymach J, Langmuir P, Kennedy S, Tada H and Johnson B: Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 11: 619-626, 2010.
39. John T, Liu G and Tsao MS: Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. Oncogene 28(Suppl 1): S14-23, 2009.
40. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J, Heckel A and Rettig WJ: BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 68: 4774-4782, 2008.
41. Mross K, Stefanic M, Gmehling D, Frost A, Baas F, Unger C, Strecker R, Henning J, Gaschler-Markefski B, Stopfer P, de Rossi L and Kaiser R: Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res 16: 311-319, 2010.
42. Lee CP, Attard G, Poupard L, Nathan PD, de Bono JS, Temple GM, Stefanic M, Padhani AR, Judson IR and Rustin GJ: A phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) in patients with advanced solid malignancies. J Clin Oncol 23: 3054, 2005.
43. Mross K, Strecker R, Frost A, Unger C, Hennig J, Stefanie M, Stopfer P, Deichsel G, Stehle G and De Rossi L: Safety, pharmakokinetics and pharmacodynamics (DCE-MRI) in patients with metastatic colorectal cancer treated in a phase I study with BIBF 1120, the first triple angiokinase inhibitor; Proceedings, AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: 55(A51), 2005.
44. Lee CP, Taylor NJ, Attard G, Nathan PD, de Bono JS, Temple GM, Tang A, Padhani AR, Judson IR and Rustin GJ: A phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) given continuously to patients with advanced solid tumours, incorporating dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). J Clin Oncol 24: 3015, 2006.
45. von Pawel J, Kaiser R, Eschbach C, Love J, Staab A, Freiwakd M, Bruno R, Stopfer P, Gatzemeier U and Reck M: Efficacy, safety and pharmacokinetic (PK) results of a phase II study with the triple angiokinase inhibitor BIBF 1120 in patients suffering from advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 3: S61, 2008.
46. Ledermann JA, Rustin GJ, Hackshaw A, Kaye SB, Jayson G, Gabra H, James LE, Bell S, Temple G, Gabra H, James LE, Bell S and Temple G: A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC). J Clin Oncol 27, 2009.
47. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A, Himmelsbach F, Rettig WJ, Meyerson M, Solca F, Greulich H and Wong KK: BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27: 4702-4711, 2008.
48. Minkovsky N and Berezov A: BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors. Curr Opin Investig Drugs 9: 1336-1346, 2008.
49. Mito K, Kashima K, Kikuchi H, Daa T, Nakayama I and Yokoyama S: Expression of polo-like kinase (PLK1) in non-Hodgkin's lymphomas. Leuk Lymphoma 46: 225-231, 2005. (Pubitemid 40185952)
50. Eskens FA, Mom CH, Planting AS, Gietema JA, Amelsberg A, Huisman H, van Doorn L, Burger H, Stopfer P, Verweij J and de Vries EG: A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer 98: 80-85, 2008.
51. Agus DB, Terlizzi E, Stopfer P, Amelsberg A and Gordon MS: A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumours. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I 24: Abstract 2074, 2006.
52. Lewis N, Marshall J, Amelsberg A, Cohen RB, Stopfer P, Hwang J and Malik S: A phase I-dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a 3-week on 1-week off schedule in patients with advanced solid tumours. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I 24: Abstract 3091, 2006.
53. Mom CH, Eskens FA, Gietema JA, Nooter K, De Jonge MJ, Amelsberg A, Huisman H, Stopfer P, De Vries EG and Verweij J: Phase I study with BIBW 2992, an irreversible dual tyrosine kinase inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) in a 2-week on, 2-week off schedule. J Clin Oncol 24: S3025, 2006.
54. Von Hoff DD, Taylor C, Rubin S, Cohen J and Garland L: A Phase I and pharmacokinetic study of HMN-214, a novel oral polo-like kinase inhibitor, in patients with advanced solid tumors. ASCO Meeting Abstracts 22: 3034, 2004.
55. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
56. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN and Rubin P: CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13: 176-181, 2003. (Pubitemid 36962641)
57. Larsen AK, Poindessous V, Kamsu-Kom N, Ouaret D, Escargueil A, El Ouadrani K, Quintas D, Dartigues P, Dumont S, Solca F, Hilberg F, Stehle G and de Gramont A: A flexible and active regimen for combining the triple angiogenesis inhibitor BIBF 1120 and the irreversible EGFR/HER2 inhibitor BIBW 2992 in colorectal cancer models. Presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. San Francisco, CA, USA, 2009.
58. Dutt A, Salvesen H, Chen TH, Ramos A, Onforio R, Hatton C, Nicoletti R, Winckler W, Grewal R, Hanna M, Wyhs N, Ziaugra L, Richter D, Trovik J, Engelsen I, Stefansson I, Fennell T, Cibulskis K, Zody M, Akslen L, Gabriel S, Wong K, Sellers WR, Meyerson M and Greulich H: Drug-sensitive FGFR2 mutations in endometrial cancer. Proc Natl Acad Sci USA 105: 8713-8717, 2008.
59. Stopfer P, Droz JP, Flechon A, Joly F, de Mont-Serrat H, Kaiser R and Oudard S: Pharmacokinetic analysis of two dosing schedules of the angiokinase inhibitor BIBF 1120 in patients with hormone-refractory prostate cancer who progressed after docetaxel treatment. Proceedings of the European Cancer Organisation and European Society for Medical Oncology congress, 20-24 September; Berlin, Germany, 2009.
60. Stopfer P, Freiwald M, Liesenfeld K-H, Bruno R, Hodge L, Eschbach C, Reck M, von Pawel J, Kaiser R and Staab A: A population pharmacokinetic analysis for BIBF 1120, an angiokinase inhibitor, in patients with advanced non-small cell lung cancer. Proceedings of the European Cancer Organisation and European Society for Medical Oncology congress, 20-24 September; Berlin, Germany, 2009.
61. Kaneda H, Okamoto I, Satoh T, Arao T, Nishio K, Sarashina A, Konishi K, Stopfer P, Kaiser R and Nakagawa K: Phase I dose-escalationstudy of continuous oral treatment with the angiokinase inhibitor BIBF 1120 in patients with advanced solid tumours. Eur J Cancer Suppl 7, 2009.
62. Yu J, Kane S, Wu J, Benedettini E, Li D, Reeves C, Innocenti G, Wetzel R, Crosby K, Becker A, Ferrante M, Cheung WC, Hong X, Chirieac LR, Sholl LM, Haack H, Smith BL, Polakiewicz RD, Tan Y, Gu TL, Loda M, Zhou X and Comb MJ: Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res 15: 3023-3028, 2009.
63. BIBW 2992 Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation. 2009 24 September 2009 [cited 5 October 2009]; Available from: http://clinicaltrials.gov/ct2/show/NCT00949650?term=LUX-Lung+3&rank=1